SHANGHAI, May 21 (Reuters) - Eli Lilly said on Tuesday its tirzepatide drug has received approval from Chinese regulators for use to treat type 2 diabetes.

Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro and weight-loss drug Zepbound. (Reporting by Andrew Silver; Editing by Muralikumar Anantharaman)